MET and lung carcinoma: These results confirmed previous findings that c-MET-amplified tumor cells become dependent on HGF for survival upon pharmacologic MET inhibition [68], as well as for lung cancer cells harboring EGFR mutations upon treatment with EGFR TKI gefitinib [65,69].